Search
User Profile
Change
Select your user profile
tags
Simplify your lab’s workflow with cobas® Respiratory flex

Acute respiratory tract infections are significant causes of morbidity and mortality worldwide.1-5 Many acute respiratory illnesses present with similar symptoms, with different types of treatment available for some illnesses. Therefore, quick and accurate identification of the viral pathogen causing the symptoms can lead to proper treatment within an effective time frame and help prevent further transmission.

Roche is excited to share that the cobas®  Respiratory flex assay is now included on the Australian Register of Therapeutics Goods, and is available in Australia.

cobas Respiratory flex for use on the cobas 5800/6800/8800 systems is an automated, multiplex, nucleic acid test that utilises real-time polymerase chain reaction (PCR) technology for simultaneous in vitro qualitative detection and differentiation of 12 viral targets from one well: 

Pathogens Detected

  • Influenza A
  • Influenza B
  • Respiratory syncytial virus (RSV)
  • SARS-CoV-2 (COVID-19)
  • Adenovirus
  • Human metapneumovirus
  • Enterovirus/rhinovirus
  • Parainfluenza 1
  • Parainfluenza 2
  • Parainfluenza 3
  • Parainfluenza 4
  • Coronavirus (229E, OC43, NL63, HKU1)

By consolidating your testing on your existing cobas 5800, 6800, and 8800 systems, this assay optimises lab resources and simplifies lab logistics to streamline operations and enhance efficiency:

instrument

Streamlined and  automated workflow -existing cobas 5800/6800/8800 systems are ready right now

instrument

cobas Respiratory flex offers the flexibility of digital reflex - promotes diagnostic stewardship by testing only what’s needed

time

Simplify lab logistics by offering a customisable solution from a single test kit

About TAGS (Temperature-Activated Generation of Signal) technology

cobas Respiratory flex utilises the new TAGS multiplex technology (Temperature Activated Generation of Signal) to differentiate up to three targets per fluorescence channel, enabling the detection and differentiation of up to 15 diagnostic results per well, from a single test kit.

There is no requirement to upgrade the hardware or software of existing cobas 5800, 6800 and 8800 systems - laboratories will immediately be able to experience fast, accurate, high throughput flexible syndromic multiplex PCR testing with digital reflex. Watch the TAGS video to learn more. 

For more information, please complete the contact form below:

Form Successfully Submitted!
Thank you for your submission!
text
close

References

1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404-6.

2. Ghebrehewet S, MacPherson P, Ho A. Influenza. BMJ. 2016;355:i6258

3. World Health Organization. The global burden of disease: 2004 update. Published: 2 Mar 2004; Accessed 29 Jan 2024. https://iris.who.int/bitstream/handle/10665/43942/9789241563710_eng.pdf?sequence=1.

4. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet. 2017;390:946-58.

5. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238-45.